At EPA Amsterdam 2026, Fernando Ventureira, CEO of Stratence Partners, presented two sessions addressing critical challenges for pharmaceutical and MedTech companies: mastering Gross to Net complexity and embedding AI into commercial decision making. This article summarizes the key insights on how organizations can transform pricing, access, and commercial execution into a unified performance system.

In Medical Devices, margin erosion rarely comes from innovation. It comes from fragmented commercial governance. Stratence Partners explains how Commercial Transformation, AI Powered, restores structural control and delivers measurable EBIT impact within year one.